Melbourne-based Neuren Pharmaceuticals (ASX:NEU) announced strong financial results for the full year 2025, driven by the continued commercial success of DAYBUE (trofinetide) in the United States.
Neuren's partner, Acadia Pharmaceuticals, reported full-year DAYBUE net sales of US$391 million, representing a 12% year-on-year increase and meeting prior guidance.
Growth accelerated in the final quarter, with Q4 sales reaching a record US$110 million, up 13% against the previous corresponding period.
This commercial momentum translated into returns for Neuren, which earned $65 million in royalty income for 2025, a 15% increase over 2024.
The final quarter contributed $20 million to this total, marking a 21% increase over the third quarter of 2025.
Patient uptake also reached new heights, with a record 1,070 unique patients receiving shipments in Q4.
76% of new prescriptions originated from community physicians, signalling broad market adoption beyond specialised centres of excellence.
Acadia has provided 2026 net sales guidance of US$460–490 million, which is expected to generate $70–$77 million in royalties for Neuren.
The outlook excludes potential EU sales and is bolstered by the Q1 2026 launch of DAYBUE STIX, a new powder formulation approved by the FDA in December 2025.
Neuren CEO Jon Pilcher noted that this sustained growth strengthens the company’s financial position.At the time of reporting, Neuren Pharmaceuticals' share price was $13.55.